Literature DB >> 25630452

Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation.

Siraj M Ali1, Vincent A Miller1, Jeffrey S Ross1, Sumanta K Pal2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25630452     DOI： 10.1016/j.eururo.2015.01.015

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  8 in total

1.  Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.

Authors:  Julia A Elvin; Laurie M Gay; Rita Ort; Joseph Shuluk; Jennifer Long; Lauren Shelley; Ronald Lee; Zachary R Chalmers; Garrett M Frampton; Siraj M Ali; Alexa B Schrock; Vincent A Miller; Philip J Stephens; Jeffrey S Ross; Richard Frank
Journal:  Oncologist       Date:  2017-03-10

2.  National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.

Authors:  Sumanta Kumar Pal; Neeraj Agarwal; Stephen Anthony Boorjian; Noah M Hahn; Arlene O Siefker-Radtke; Peter E Clark; Elizabeth R Plimack
Journal:  J Clin Oncol       Date:  2016-07-25       Impact factor: 44.544

Review 3.  Translating cancer genomes and transcriptomes for precision oncology.

Authors:  Sameek Roychowdhury; Arul M Chinnaiyan
Journal:  CA Cancer J Clin       Date:  2015-11-03       Impact factor: 508.702

4.  Novel therapies in urothelial carcinoma: a biomarker-driven approach.

Authors:  G Iyer; J E Rosenberg
Journal:  Ann Oncol       Date:  2018-12-01       Impact factor: 32.976

Review 5.  Going to extremes: determinants of extraordinary response and survival in patients with cancer.

Authors:  Flurina A M Saner; Alan Herschtal; Brad H Nelson; Anna deFazio; Ellen L Goode; Susan J Ramus; Ahwan Pandey; Jessica A Beach; Sian Fereday; Andrew Berchuck; Stephanie Lheureux; Celeste Leigh Pearce; Paul D Pharoah; Malcolm C Pike; Dale W Garsed; David D L Bowtell
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

Review 6.  Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds.

Authors:  Panagiotis Zoumpourlis; Giannicola Genovese; Nizar M Tannir; Pavlos Msaouel
Journal:  Clin Genitourin Cancer       Date:  2020-12-02       Impact factor: 2.872

7.  Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma.

Authors:  Wassim Abida; Matthew I Milowsky; Irina Ostrovnaya; Scott R Gerst; Jonathan E Rosenberg; Martin H Voss; Andrea B Apolo; Ashley M Regazzi; Asia S McCoy; Mariel E Boyd; Dean F Bajorin
Journal:  Bladder Cancer       Date:  2016-01-07

8.  Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma.

Authors:  Monika Joshi; Monali Vasekar; Petros Grivas; Hamid Emamekhoo; JoAnn Hsu; Vincent A Miller; Philip J Stephens; Siraj M Ali; Jeffrey S Ross; Junjia Zhu; Joshua Warrick; Joseph J Drabick; Sheldon L Holder; Matthew Kaag; Min Li; Sumanta Kumar Pal
Journal:  Oncotarget       Date:  2016-08-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.